Simultaneous determination of LY3214996, abemaciclib, and M2 and M20 metabolites in human plasma, cerebrospinal fluid, and brain tumor by LC-MS/MS

Margaryan, Tigran; Elliott, Mackenna; Sanai, Nader; Tovmasyan, Artak

doi:10.1016/j.jpha.2022.05.003

Cited by 5 publications

(4 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The limit of detection (LOD) of AMC was determined to be 2.7 nM (3S b /m). This value of detection limit and the linear dynamic range for AMC observed for the ds-DNA/PP/Ce-doped H-NiO-ND/PGE are comparable and better than those obtained for several other previous studies (Table 1) (Margaryan et al, 2022;Turkovic et al, 2022;Martínez-Chávez et al, 2021). The detection limit of only several LC-MS/MS method developed for detection of AMC was superior to our sensor.…”

Section: Dynamic Ranges Detection Limitssupporting

confidence: 84%

“…One of the common treatments for some breast cancers has been approved to be Abemaciclib (AMC) (Figure 1), especially in combination (Margaryan et al, 2022), which is able to cross the blood-brain barrier (BBB) and inhibit tumor growth (Raub et al, 2015). Findings of a study on a physiologically oriented pharmacokinetic model recommended that AMC be used to treat brain cancer, which is preferable to other CDK4/ 6 inhibitors like palbociclib and ribociclib (Li et al, 2021).…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Detection of abemaciclib, an anti-breast cancer agent, using a new electrochemical DNA biosensor

Lei

Alwan²,

Alamir

et al. 2022

Front. Chem.

View full text Add to dashboard Cite

Detection of DNA molecules and possible chemotherapy-induced changes in its structure has been the goal of researchers using rapid, sensitive and inexpensive approaches. Therefore, the aim of this study was to fabricate a new electrochemical DNA biosensor using pencil graphite electrodes modified with polypyrrole/Ce doped hexagonal nickel oxide nanodisks or PP/Ce-doped H-NiO-ND composites for determination of Abemaciclib (AMC) and ds-DNA molecules. The DNA biosensor was prepared by immobilizing ds-DNA on the surface of PP/Ce-doped H-NiO-ND/PGE. Differential pulse voltammetry (DPV) was used to electrochemically detect AMC. The results elucidate the extremely high sensitivity of the ds-DNA/PP/Ce-doped H-NiO-ND/PGE biosensor to AMC, with a narrow detection limit of 2.7 nM and a lengthy linear range of 0.01–600.0 μM. The admirable performance of as-fabricated biosensor could be related to the active reaction sites and the unique electrochemical response related to the nanocomposites by enhancing ds-DNA stabilization and accelerating electron transfer on the surface of electrode.

show abstract

Section: Dynamic Ranges Detection Limitssupporting

confidence: 84%

Section: Introductionmentioning

confidence: 99%

Detection of abemaciclib, an anti-breast cancer agent, using a new electrochemical DNA biosensor

Lei

Alwan²,

Alamir

et al. 2022

Front. Chem.

View full text Add to dashboard Cite

show abstract

“…After centrifugation at 1500× g for 10 min, the supernatant was stored short-term at −18 • C and long-term at −80 • C. The plasma was thawed at room temperature for 30 min before any experiments were conducted. Research approvals were obtained from the Ethics Committee of the University of Zagreb Faculty of Pharmacy and Biochemistry (approval 251-62-03- [19][20][21][22][23][24][25][26][27][28][29][30] and the Ethics Committee of University Hospital Centre Zagreb (approval 02/21-JG).…”

Section: Plasma Sample Pretreatmentmentioning

confidence: 99%

“…Most of the methods were developed only for selected combinations of the analytes, with three works focused on all six drugs of interest, applying protein precipitation (PPT) and dispersive liquidliquid microextraction (DLLME) for sample preparation [5,11,12]. For specific analyte combinations, the most common sample preparation procedure applied was PPT with an organic solvent [13][14][15][16][17][18][19][20], liquid-liquid extraction (LLE) [21,22], and SPE [14,[23][24][25]. Of the SPE methods applied for some of the analytes of interest, an Oasis HLB sorbent in combination with methanol (MeOH) as the elution solvent was found suitable for the CDKi [24,25], as well as a Phenomenex C18 sorbent eluted with acetonitrile (ACN) following PPT [14].…”

Section: Introductionmentioning

confidence: 99%

Optimisation of Solid-Phase Extraction and LC-MS/MS Analysis of Six Breast Cancer Drugs in Patient Plasma Samples

Turković,

Mutavdžić Pavlović,

Mlinarić

et al. 2023

Pharmaceuticals

View full text Add to dashboard Cite

In the development of bioanalytical LC-MS methods for the determination of drugs in plasma samples in a clinical setting, adequate sample preparation is of utmost importance. The main goals are to achieve the selective extraction of the analytes of interest and attain thorough matrix removal while retaining acceptable ecological properties, cost-effectiveness, and high throughput. Solid-phase extraction (SPE) offers a versatile range of options, from the selection of an appropriate sorbent to the optimisation of the washing and elution conditions. In this work, the first SPE method for the simultaneous extraction of six anticancer drugs used in novel therapeutic combinations for advanced breast cancer treatment—palbociclib, ribociclib, abemaciclib, anastrozole, letrozole, and fulvestrant—was developed. The following sorbent chemistries were tested: octylsilyl (C8), octadecylsilyl (C18), hydrophilic–lipophilic balance (HLB), mixed-mode cation-exchange (MCX and X-C), and mixed-mode weak cation-exchange (WCX), with different corresponding elution solvents. The samples were analysed using LC-MS/MS, with a phenyl column (150 × 4.6 mm, 2.5 μm). The best extraction recoveries (≥92.3%) of all analytes were obtained with the C8 phase, using methanol as the elution solvent. The optimised method was validated in the clinically relevant ranges, showing adequate precision (inter-day RSD ≤ 14.3%) and accuracy (inter-day bias −12.7–13.5%). Finally, its applicability was successfully proven by the analysis of samples from breast cancer patients.

show abstract

Dispersive liquid-liquid microextraction followed by sweeping micellar electrokinetic chromatography-tandem mass spectrometry for determination of six breast cancer drugs in human plasma

Mlinarić,

Turković,

Sertić

2024

Journal of Chromatography A

View full text Add to dashboard Cite

Simultaneous determination of LY3214996, abemaciclib, and M2 and M20 metabolites in human plasma, cerebrospinal fluid, and brain tumor by LC-MS/MS

Cited by 5 publications

References 22 publications

Detection of abemaciclib, an anti-breast cancer agent, using a new electrochemical DNA biosensor

Detection of abemaciclib, an anti-breast cancer agent, using a new electrochemical DNA biosensor

Optimisation of Solid-Phase Extraction and LC-MS/MS Analysis of Six Breast Cancer Drugs in Patient Plasma Samples

Dispersive liquid-liquid microextraction followed by sweeping micellar electrokinetic chromatography-tandem mass spectrometry for determination of six breast cancer drugs in human plasma

Contact Info

Product

Resources

About